

CPT® Editorial Summary of Panel Actions November 2022

Please be aware that this action is a reflection of the discussion at the most recent virtual Panel meeting.

The SARS-CoV-2 Vaccine product CPT code and immunization CPT codes can be found on the [AMA Website](#).

Addition of 2 Category I codes (0164A, 91316) accepted by the CPT Editorial Panel. Codes 0164A, 91316, and all related references will be published in CPT 2024. Guidelines and parenthetical notes are only effective for codes that have received FDA Emergency Use Authorization (EUA) approval.

- Updated effective date for codes 0134A, 0144A, 0154A, 91313, 91314, and 91315.
- Removal of FDA approval pending symbol (↗) from codes 91314 and 91315.
- Updated code range to 91300-91316 by replacing 91315 with 91316 throughout the code set.
- Updated Appendix Q table to revise the patient ages for code 91313.

*Codes 0134A and 91313 for patient aged 18 years and older are effective August 31, 2022, and patient aged 12 years through 17 years are effective October 12, 2022.

Name	Code #	Description of Editorial Panel Action	Effective Date
Immunization administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines only	#●0164A	Accepted addition of code 0164A for immunization administration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine only. Each administration code is specific to each individual vaccine product (eg, 91316); accepted revision of Appendix Q Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) Vaccines, a quick reference guide to showcase the coding structure for SARS-CoV-2 vaccine CPT reporting, to include code 0164A; and accepted revision of the guidelines in the Medicine Services, Immunization Administration for Vaccines/Toxoids, and the Vaccines, Toxoid subsections.	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccines	#↗●91316	Accepted addition of code 91316 to report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccines; accepted revision of Appendix Q Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) Vaccines, a quick reference guide to showcase the coding structure for SARS-CoV2 vaccine CPT reporting, to include code 91316; and accepted revision of the guidelines in the Medicine Services, Immunization Administration for Vaccines/Toxoids, and the Vaccines, Toxoid subsections.	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration